The in vitro susceptibilities of 83 clinical isolates of Brucella melitensis to seven cephalosporins and a monobactam were determined. Ceftizoxim.e, ceftriaxone, and cefotaxime were the most effective agents tested, with MICs ranging from 0.25 to 2 ,ig/mI. Moxalactam, cefoperazone, cefuroxime, and cettazidime showed MICs between 4 and 64 ,ug/ml, with moxalactam being the most active agent in this group. Aztreonam showed poor activity, with MICs higher than 64 ,Ig/ml.
A few antimicrobial combinations are widely accepted for the treatment of acute brucellosis, and the disease, as well as its most frequent complications, can be adequately controlled with these drugs (11) . However, these conventional therapeutic regimens have given poor results when used in the treatment of brucella meningoencephalitis (4), a severe complication of not uncommon occurrence in highly endemic areas of brucellosis. The bacteriostatic nature of the tetracyclines and the poor penetration of streptomycin into the cerebrospinal fluid may be the causes of this therapeutic failure, in view of recent evidence suggesting the requirement of bactericidal concentrations of antibiotics in the cerebrospinal fluid for the control of bacterial meningitis (10) .
Cephalosporin antibiotics are not included in any of the commonly accepted regimens for the treatment of brucellosis. Hall and Manion (6) found that concentrations of cephalosporins up to 100 p.g/ml were needed to inhibit 100% of their strains. However, some of the new expandedspectrum cephalosporins have properties which are very desirable in any drug potentially useful in central nervous system infections. They are bactericidal and very active against most gram-negative bacilli, as well as the conventional pathogens of meningitis, and they achieve reasonably good levels' in the cerebrospinal fluid in the presence of inflamed meninges (7). Gutidrrez Altds et al. (5) recently reported good in vitro activity of imipenem against Brucella melitensis, and Young (12) successfully treated a case of meningitis due to Brucella suis with a combination of moxalactam and rifampin. These reports encouraged us to test the activity of a number of expanded-spectrum cephalosporins and a monobactam, reported to show reasonably good penetration into the central nervous system (7) .
A total of 83 B. melitensis strains isolated from human blood cultures were tested. The strains were identified by standard methods (1) data on brucella susceptibility (3, 5) and other opinions as to the treatment of bru9ella meningoencephalitis in the literature (12), we suggest that a potentially effective treatment of the severe complication>of brucella meningoencephalitis includes rifampin associated with another antibiotic. The data presented here indicate that ceftizoxime and ceftriaxone could be the appropriate choices for this second drug. Both enter the cerebroEpinal fluid at approximately the same rate, with mean concentrations of 8.5 p.g/ml for ceftizoxime and 9.5 Fg/ml for ceftriaxone (2, 8) , that is, 10 to 40 times the MICs for our strains. Ceftriaxone has, the advantage of a much longer half-life than ceftizoxime, permitting a twicedaily dosage (9) . This may be convenient in long-term treatments.
